Radiation Therapy Program and Breast Cancer Outcomes Unit, British Columbia Cancer Agency, Vancouver Island Centre, University of British Columbia, Victoria, British Columbia, Canada.
Radiation Therapy Program and Breast Cancer Outcomes Unit, British Columbia Cancer Agency, Vancouver Island Centre, University of British Columbia, Victoria, British Columbia, Canada.
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):556-62. doi: 10.1016/j.ijrobp.2014.03.016.
To identify clinical and pathological factors that identify groups of women with stage I breast cancer with a 5-year risk of local recurrence (LR) ≤1.5% after breast-conserving therapy (BCS) plus whole-breast radiation therapy (RT).
Study subjects were 5974 patients ≥50 years of age whose cancer was diagnosed between 1989 and 2006, and were referred with pT1 pN0 invasive breast cancer treated with BCS and RT. Cases of 5- and 10-year LR were examined using Kaplan-Meier methods. Recursive partitioning analysis was performed in patients treated with and without endocrine therapy to identify combinations of factors associated with a 5-year LR risk ≤1.5%.
The median follow-up was 8.61 years. Median age was 63 years of age (range, 50 to 91). Overall 5-year LR was 1.5% (95% confidence interval [CI], 1.2%-1.9%) and 10-year LR was 3.4% (95% CI, 2.8%-4.0%). Of 2830 patients treated with endocrine therapy, patient subsets identified with 5-year LR ≤1.5% included patients with grade 1 histology (n=1038; LR, 0.2%; 95% CI, 0%-0.5%) or grade 2 histology plus ≥60 years of age (n=843; LR, 0.5%; 95% CI, 0%-1.0%). Ten-year LR for these groups were 0.8% (95% CI, 0.1%-1.6%) and 0.9% (95% CI, 0.2%-1.6%), respectively. Of 3144 patients treated without endocrine therapy, patients with grade 1 histology plus clear margins had 5-year LR ≤1.5% (n=821; LR, 0.6%; 95% CI, 0.1%-1.2%). Ten-year LR for this group was 2.2% (95% CI, 1.0%-3.4%).
Histologic grade, age, margin status, and use of endocrine therapy identified 45% of a population-based cohort of female patients over age 50 with stage I breast cancer with a 5-year LR risk ≤1.5% after BCS plus RT. Prospective study is needed to evaluate the safety of omitting RT in patients with such a low risk of LR.
确定临床和病理因素,以确定一组接受保乳治疗(BCS)加全乳房放疗(RT)后的Ⅰ期乳腺癌患者,其 5 年局部复发(LR)风险≤1.5%。
本研究对象为 5974 名年龄≥50 岁的患者,其癌症于 1989 年至 2006 年间被诊断为 pT1 pN0 浸润性乳腺癌,接受 BCS 和 RT 治疗。采用 Kaplan-Meier 方法检查 5 年和 10 年 LR。对接受内分泌治疗和未接受内分泌治疗的患者进行递归分区分析,以确定与 5 年 LR 风险≤1.5%相关的因素组合。
中位随访时间为 8.61 年。中位年龄为 63 岁(范围为 50-91 岁)。总体 5 年 LR 为 1.5%(95%置信区间[CI],1.2%-1.9%),10 年 LR 为 3.4%(95% CI,2.8%-4.0%)。在 2830 名接受内分泌治疗的患者中,5 年 LR≤1.5%的患者亚组包括组织学分级 1 级(n=1038;LR,0.2%;95%CI,0%-0.5%)或组织学分级 2 级加≥60 岁(n=843;LR,0.5%;95%CI,0%-1.0%)。这些组的 10 年 LR 分别为 0.8%(95% CI,0.1%-1.6%)和 0.9%(95% CI,0.2%-1.6%)。在未接受内分泌治疗的 3144 名患者中,组织学分级 1 级加切缘清晰的患者 5 年 LR≤1.5%(n=821;LR,0.6%;95%CI,0.1%-1.2%)。该组的 10 年 LR 为 2.2%(95% CI,1.0%-3.4%)。
组织学分级、年龄、切缘状态和内分泌治疗的应用确定了 50 岁以上Ⅰ期乳腺癌患者的 45%,这些患者在接受 BCS 加 RT 治疗后 5 年的 LR 风险≤1.5%。需要前瞻性研究来评估在 LR 风险如此低的患者中省略 RT 的安全性。